Trial · NCT04834024
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
NCT04834024, Phase 3, Unknown, Beijing Mabworks Biotech Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma. Trials, record NCT04834024. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04834024
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
- NCT number
- NCT04834024
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 168 participants, estimated
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Conditions
- Follicular Lymphoma and Marginal Zone Lymphoma
- Interventions
- Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide
- First posted
- 2021-04-06
- Last updated
- 2024-11-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (per IRC) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Progression-free Survival (per Investigator) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Overall Survival | From date of randomization Until date of death from any cause for up to 5 years | |
| Secondary | Overall Response Rate (ORR) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Kaplan-Meier Estimate of Duration of Response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Percentage of Participants With Disease Control | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Number of Participants With Treatment Emergent Adverse Events | up to the 1 month the last dose of last subject |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39007066 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04834024
GET https://conductscience.org/api/trials/v1/NCT04834024/registered